Edition:
United States

Insulet Corp (PODD.OQ)

PODD.OQ on NASDAQ Stock Exchange Global Select Market

42.82USD
26 May 2017
Change (% chg)

$0.12 (+0.28%)
Prev Close
$42.70
Open
$42.59
Day's High
$42.93
Day's Low
$42.20
Volume
149,985
Avg. Vol
158,945
52-wk High
$48.22
52-wk Low
$27.65

Latest Key Developments (Source: Significant Developments)

Insulet reports Q1 loss per share $0.17
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Insulet Corp :Insulet reports first quarter 2017 financial results.Q1 loss per share $0.17.Q1 revenue $101.7 million versus I/B/E/S view $97.8 million.Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue up 18 percent.Insulet Corp says insulet raises mid-point of full year 2017 revenue guidance.Insulet Corp says for year ending December 31, 2017, raising mid-point of its revenue guidance and is now expecting a range of $425 to $440 million.Insulet Corp says for quarter ending June 30, 2017, company is introducing revenue guidance in range of $104 to $108 million.FY2017 revenue view $432.0 million -- Thomson Reuters I/B/E/S.Q2 revenue view $104.5 million -- Thomson Reuters I/B/E/S.  Full Article

Insulet reports Q4 revenue $103.6 million
Monday, 27 Feb 2017 04:01pm EST 

Insulet Corp : Insulet reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.16 from continuing operations . Q4 revenue $103.6 million versus I/B/E/S view $100.6 million . Q4 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S . Sees FY 2017 revenue up about 17 percent . Sees FY 2017 revenue $420 million to $440 million .For quarter ending March 31, 2017, company expects to generate revenue in range of $96 to $99 million.  Full Article

Insulet Q3 loss per share $0.05 from continuing operations
Thursday, 3 Nov 2016 04:01pm EDT 

Insulet Corp : Insulet corp sees q4 revenues $99 to $102 million . Insulet reports third quarter 2016 financial results . Q3 loss per share $0.05 from continuing operations . Q3 revenue $94.9 million versus i/b/e/s view $89.7 million . Q3 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S .Sees fy 2016 revenue $362 million to $365 million.  Full Article

Insulet announces private offering of convertible senior notes
Tuesday, 6 Sep 2016 04:05pm EDT 

Insulet Corp : Insulet announces private offering of convertible senior notes .Insulet Corp says to offer $250 million principal amount of convertible senior notes due 2021 (notes) in a private placement.  Full Article

Insulet Corp reports Q2 loss per share of $0.08 from cont ops
Wednesday, 3 Aug 2016 04:01pm EDT 

Insulet Corp : Insulet reports second quarter 2016 financial results . Q2 loss per share $0.08 from continuing operations . Q2 revenue $87.3 million versus I/B/E/S view $81.2 million . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Sees revenue guidance for 2016 in range of $345 to $355 million .FY2016 revenue view $337.4 million -- Thomson Reuters I/B/E/S.  Full Article

Insulet Corp reaffirms FY 2016 revenue guidance; gives Q2 2016 revenue guidance
Thursday, 28 Apr 2016 04:01pm EDT 

Insulet Corp:For FY 2016, the Company is reaffirming its revenue guidance of $330 to $350 million.For Q2 2016, the Company is introducing revenue guidance in the range of $81 to $84 million.  Full Article

Insulet Corp announces development partner for the omnipod artificial pancreas
Thursday, 25 Feb 2016 07:00am EST 

Insulet Corp:License agreement and partnership with Mode AGC to develop and incorporate advanced artificial pancreas algorithm created by renowned researchers Francis Doyle PhD, Eyal Dassau PhD, and Howard Zisser MD.  Full Article

Insulet Corporation to divest neighborhood diabetes supplies business
Tuesday, 2 Feb 2016 04:15pm EST 

Insulet Corporation:To divest neighborhood diabetes supplies business.To sell wholly-owned neighborhood diabetes supplies business for $5 million in cash.Transaction is expected to improve insulet's gross margins on an annual basis by low-to-mid single digits.Says company expects non-recurring charges of approximately $10 million in the fourth quarter of 2015.Says company expects additional charges in the first quarter of 2016.Transaction to be accretive to earnings, excluding non-recurring charges,transition costs related to the sale of the business.Says Covington associates acted as financial advisor and hogan lovells US llp acted as legal advisor to Insulet.Says to sell its wholly-owned neighborhood diabetes supplies business to liberty medical, llc.  Full Article

Insulet Corp enters into development agreement with Eli Lilly for OmniPod Delivery of U200 Concentrated Insulin
Monday, 11 Jan 2016 05:00pm EST 

Insulet Corp:Announced it has entered into a development agreement with Eli Lilly and Company (Lilly) to develop a new version of Insulet's OmniPod tubeless insulin delivery system, specifically designed to deliver Lilly's Humalog 200 units/mL insulin.  Full Article

Insulet Corp Issues Voluntary Recall of OmniPod Insulin Management System - FDA
Wednesday, 26 Aug 2015 08:00pm EDT 

Insulet Corp:On July 8, Insulet Corporation (Insulet or the Company) initiated a lot-specific voluntary recall of 40,846 boxes (10 Pods per box) of the OmniPod (Pod) Insulin Management System - FDA.This field corrective action is due to the possibility that some of the Pods from these lots may have a higher rate of failure than Insulet's current manufacturing standards - FDA.This recall does not affect the OmniPod Personal Diabetes Manager (PDM) - FDA.The affected Pod lots have resulted in 90 Medical Device Reports of which 13 required medical intervention. No serious injuries or deaths have been reported in patients using OmniPod devices from the affected lots - FDA.  Full Article

More From Around the Web

BRIEF-Insulet announces positive results from feasibility study of diabetes drug

* Announced positive results from first feasibility study of omnipod horizon(tm) hybrid closed-loop system Source text for Eikon: Further company coverage: